DENVER–(BUSINESS WIRE)–HempFusion Wellness Inc. (TSX:CBD.U) (US:CBDHF) (FWB:8OO) (“HempFusion” or the “Company”), a leading health and wellness CBD company utilizing the power of whole-food hemp nutrition, is pleased to announce it has completed, in collaboration with the Inflammatory Markers Laboratory (“IML”) located in Wichita, Kansas, a pilot study that assessed the effect of the HempFusion formulation CBD Capsules® (HempFusion 20mg CBD capsules with botanical terpenes) as it relates to a combination of anti-inflammatories in lowering the results of the chronic inflammation test (which measures urinary 11-dehydro thromboxane B2, the stable end product of intracellular thromboxane metabolism that has been shown to correlate with inflammation) and has released a white paper titled “Oral Formulation May Modulate Thromboxane Production”i.
Results of the pilot study have shown potential promise in the area of inflammatory markers and possible effects on exaggerated inflammation.
“Our laboratory has demonstrated the effectiveness of numerous products in reducing thromboxane production,” commented Gordon Ens, Director of IML. “I was pleased to see a CBD product show such a significant reduction of thromboxane in this pilot trial.”
The white paper, expected to be published shortly, is co-authored by Gordon Ens, Director of IML and George Fritsma, Professor at University of Alabama, and illustrates the potential of tracking and elucidating biomarkers sensitive to inflammation in addition to how novel compounds and formulas modulate the expression of these markers.
Jason Mitchell, N.D., HempFusion’s Co-Founder and Chief Executive Officer commented, “We are committed to furthering research in the area of hemp-derived CBD and this pilot trial and soon to be published white paper reinforces our continued focus on the safe and effective use of hemp-derived CBD products.”
HempFusion is dedicated to research related to toxicology safety, which is evident through its involvement and co-sponsoring of the ValidCare Human Observational Safety Study, what is believed to be the largest CBD toxicology study of its kind ever completed to date. HempFusion continues to focus on research & development, pilot studies, and clinical trials, to advance the science of CBD.
HempFusion is a leading health and wellness CBD company utilizing the power of whole-food hemp nutrition. HempFusion distributes its family of brands, including HempFusion, Probulin Probiotics, Biome Research, and HF Labs, to approximately 4,000 retail locations across all 50 states of the United States and select international locations. Built on a foundation of regulatory compliance and human safety, HempFusion’s diverse product portfolio comprises 48 SKUs including tinctures, proprietary FDA Drug Listed Over-The-Counter (OTC) Topicals, Doctor/Practitioner Lines and more. With a strong focus on research and development, HempFusion has an additional 30 products under development. HempFusion is a board member of the US Hemp Roundtable, and HempFusion’s wholly-owned subsidiary, Probulin Probiotics, is one of the fastest-growing probiotics companies in the United States, according to SPINs reported data. HempFusion’s CBD products are based on a proprietary Whole Food Hemp Complex™ and are available in-store or by visiting HempFusion online at www.hempfusion.com or www.probulin.com.
Follow HempFusion on Twitter, Facebook and Instagram and Probulin on Twitter, Facebook and Instagram.
This news release contains forward-looking statements and forward-looking information within the meaning of Canadian securities legislation (collectively, “forward-looking statements“) that relate to HempFusion’s current expectations and views of future events. Any statements that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance (often, but not always, through the use of words or phrases such as “will likely result”, “are expected to”, “expects”, “will continue”, “is anticipated”, “anticipates”, “believes”, “estimated”, “intends”, “plans”, “forecast”, “projection”, “strategy”, “objective” and “outlook”) are not historical facts and may be forward-looking statements and may involve estimates, assumptions and uncertainties which could cause actual results or outcomes to differ materially from those expressed in such forward-looking statements. No assurance can be given that these expectations will prove to be correct and such forward-looking statements included in this news release should not be unduly relied upon. These statements speak only as of the date of this news release. In particular and without limitation, this news release contains forward-looking statements relating to the publication of the white paper and the Company’s plans, focus and objectives.
Forward-looking statements are based on a number of assumptions and are subject to a number of risks and uncertainties, many of which are beyond HempFusion’s control, which could cause actual results and events to differ materially from those that are disclosed in or implied by such forward-looking statements. Such risks and uncertainties include, but are not limited to, the impact and progression of the COVID-19 pandemic and other factors set forth under “Forward-Looking Statements” and “Risk Factors” in the final long form prospectus of the Company dated December 17, 2020 and available under the Company’s profile on SEDAR at www.sedar.com. HempFusion undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law. New factors emerge from time to time, and it is not possible for HempFusion to predict all of them or assess the impact of each such factor or the extent to which any factor, or combination of factors, may cause results to differ materially from those contained in any forward-looking statement. Any forward-looking statements contained in this news release are expressly qualified in their entirety by this cautionary statement.
Neither the TSX nor its Regulation Services Provider (as that term is defined in the policies of the TSX) accepts responsibility for the adequacy or accuracy of this release.
i Oral Formulation May Modulate Thromboxane Production Gordon E. Ens, BA, MT(ASCP)1, George A. Fritsma, MS, MLS2, Elaina Goldsmith, DVM1, Victoria J. Heimerman, MT(ASCP)1
1Inflammatory Markers Laboratory, Wichita, KS
2University of Alabama at Birmingham, Birmingham, AL